Submit Separate Retrospective, Prospective Study data of subjects: CDSCO Panel Tells Takeda on Velaglucerase alfa study

Written By :  Dr. Divya Colin
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-07-15 12:30 GMT   |   Update On 2024-07-15 12:30 GMT
Advertisement

New Delhi: Regarding the post-marketing surveillance study of the drug major Takeda Pharmaceutical's Velaglucerase alfa injection, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined the firm to present data separately for a retrospective and prospective study of the subjects who participated in the study and to submit patient wise data regarding size reduction of organ- liver and spleen.

Advertisement
This came after drug maker Takeda presented the post-marketing surveillance study titled: “A PMS study for VIPRIV Velaglucerase alfa 400 units/vial powder for solution for infusion in India” vide protocol No. SHP669-406 version 1.0 dated 15.11.2023.

VPRIV (velaglucerase alfa) is indicated for long-term enzyme replacement therapy (ERT) for pediatric and adult patients with type 1 Gaucher disease.

Gaucher disease type 1 (GD1) is the most common form of Gaucher disease. Like other types of Gaucher disease, GD1 is caused when not enough glucocerebrosidase (GBA) is made. GBA is an important enzyme that breaks down a fatty chemical called glucocerebroside. Because the body cannot break down this chemical, fat-filled Gaucher cells build up in areas like the spleen, liver, and bone marrow. Symptoms of GD1 include enlarged spleen and liver, low blood cell counts, bleeding problems, and bone disease. The symptoms can range from mild to severe and may appear anytime from childhood to adulthood. Gaucher disease is caused by changes in the GBA gene and is inherited in an autosomal recessive manner. Diagnosis is suspected by clinical symptoms and confirmed by measuring GBA enzyme activity or genetic testing.

At the recent SEC meeting for Endocrinology and Metabolism held on June 11, 2024, the expert panel reviewed the post-marketing surveillance study titled: “A PMS study for VIPRIV Velaglucerase alfa 400 units/vial powder for solution for infusion in India” presented by the drug major Takeda.
After detailed deliberation, the committee recommended the following:
1. The firm has to present data separately for retrospective and prospective study of the subjects who participated in the study.
2. To submit patient wise data regarding size reduction of organ- liver and spleen.
Further, the expert panel stated that the proposal will be deliberated in the presence of experts in Pediatrics Neurology/ Pediatrics genetics. Following the above, the committee suggested that the firm should submit PMS study data for further review by the committee.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News